A mix of corporate offices, healthcare and the trades supporting continuous residential construction, plus a substantial commuter population working further south.
Because intake and follow-up are handled asynchronously rather than at a scheduled appointment time, an irregular or rotating schedule is not an obstacle. You complete your part when you can; a clinician reviews it afterward.
You complete a secure online intake covering your health history, current medications and goals. A licensed clinician reviews it and may follow up by message or video. If they determine treatment is appropriate for you, they issue a prescription that goes to a licensed pharmacy, which ships to your address in McKinney. Check-ins continue online.
Not everyone qualifies. A clinician makes an independent judgment for each patient, and payment does not guarantee a prescription.
The county's medical infrastructure is concentrated toward Plano and Frisco, so eastern McKinney residents drive further than the city's size suggests.
Roughly 215,000 residents, roughly triple its population at the turn of the century. Telehealth does not add specialists to Collin County, but it does mean your evaluation is not limited to whoever has an opening near you.
McKinney is built around a preserved nineteenth-century courthouse square, with subdivisions spreading west toward US-75 and east past Lake Lavon into land that was rural a decade ago.
McKinney is the seat of Collin County and one of the fastest-growing cities in the country, which puts a preserved historic downtown at the center of relentless new development.
US-75 is the spine, with SH-121 and the Sam Rayburn Tollway connecting west toward Frisco and Plano. East of the highway, the road network thins quickly.
Online evaluation removes the trip from the equation. Your intake is completed from home, a licensed clinician reviews your history, and if treatment is appropriate a partner pharmacy ships to your McKinney address. Nothing about the process requires you to be on the road.
Compounded semaglutide is prepared by a licensed pharmacy to fill an individual prescription and is not FDA-approved. The FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed.
Semaglutide carries a boxed warning regarding thyroid C-cell tumors observed in rodents and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects are gastrointestinal — nausea, vomiting, diarrhea and constipation — and cluster after dose increases. Serious risks include pancreatitis, gallbladder disease and kidney injury from dehydration.